Literature DB >> 6214998

Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects.

K S Israel, H R Black, G L Brier, J D Wolny, K A DeSante.   

Abstract

The pharmacokinetics of moxalactam were studied in 86 normal adult male volunteers who received single or multiple doses intravenously or intramuscularly. The short absorption half-times and lag times indicate that the intramuscular dose is rapidly absorbed. The mean plasma half-life was 1.85 +/- 0.24 h for intravenous doses and 2.24 +/- 0.44 h for intramuscular doses. The mean renal clearances for intravenous doses were 0.052 and 0.067 liters/kg per h for intramuscular doses. Although moxalactam is eliminated primarily by the kidney a chromatogram of the feces from volunteers who received multiple doses showed that it is also excreted as the parent compound in to the feces via the biliary tract. The pharmacokinetics parameters of moxalactam when administered intravenously or intramuscularly in single and multiple doses clearly show the kinetics of moxalactam are linear over the dosage ranges studied and are independent of dose.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6214998      PMCID: PMC183680          DOI: 10.1128/AAC.22.1.94

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

Review 3.  Pharmacokinetics of cephalosporin antibiotics.

Authors:  J M Brogard; F Comte; M Pinget
Journal:  Antibiot Chemother (1971)       Date:  1978

4.  Pharmacokinetics of cefotaxime.

Authors:  K P Fu; P Aswapokee; I Ho; C Matthijssen; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

5.  A method to predict infinity values for biexponential processes.

Authors:  J Newburger; J G Wagner; S Stavchansky
Journal:  J Pharmacokinet Biopharm       Date:  1979-08

6.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

7.  LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.

Authors:  G M Trager; G W White; V M Zimelis; A P Panwalker
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

8.  LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

9.  In vitro activity of LY127935.

Authors:  M Barza; F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

10.  In vitro activity of LY127935.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

View more
  6 in total

1.  Pharmacokinetics of moxalactam in elderly subjects.

Authors:  M H Andritz; R P Smith; A L Baltch; P E Griffin; J V Conroy; N Sutphen; M C Hammer
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

2.  Moxalactam in nosocomial infections with Serratia marcescens.

Authors:  T Mall; F Follath; M Salfinger; R Ritz; H Reber
Journal:  Intensive Care Med       Date:  1985       Impact factor: 17.440

3.  Steady-state moxalactam pharmacokinetics in patients: noncompartmental versus two-compartmental analysis.

Authors:  D J Swanson; D P Reitberg; I L Smith; P B Wels; J J Schentag
Journal:  J Pharmacokinet Biopharm       Date:  1983-08

4.  Pharmacokinetics of cefpimizole in normal humans after single- and multiple-dose intravenous infusions.

Authors:  D B Lakings; J M Friis; R J Brown; H R Allen
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

5.  Pharmacokinetics and dose proportionality of cefpimizole in normal humans after intramuscular administration.

Authors:  D B Lakings; E Novak; J M Friis; C M Lunan; L M Paxton
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

6.  Simulating moxalactam dosage for extended-spectrum β-lactamase-producing Enterobacteriaceae using blood antimicrobial surveillance network data.

Authors:  Chen Huang; Qingyi Shi; Beiwen Zheng; Jinru Ji; Chaoqun Ying; Xiao Yu; Hui Wang; Yonghong Xiao
Journal:  Infect Drug Resist       Date:  2019-05-08       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.